A Multi Targeting Conditionally Replicating Adenovirus Displays Enhanced Oncolysis while Maintaining Expression of...

Area of Science:

• Oncolytic virology
• Cancer gene therapy
• Immunotherapy

Background:

• Oncolytic adenoviruses, specifically those with a 24 base pair deletion in the E1A gene (D24), are being investigated as potential cancer therapeutics.
• Enhancing the tumor-targeting specificity and cytotoxic efficacy of these viruses is crucial for improving their therapeutic potential.

Purpose of the Study:

• To engineer a novel conditionally replicating adenovirus with enhanced tumor targeting and oncolytic activity.
• To evaluate the efficacy of this new adenovirus compared to existing oncolytic viruses and to assess its potential for immunotherapy delivery.

Main Methods:

• Generation of a novel adenovirus by incorporating an Ad5/3 fiber with a carboxyl terminus RGD ligand into the D24 backbone.
• Assay of viral cytopathic effect and cytotoxicity across various tumor cell lines.
• Engineering the virus for the delivery of immunotherapeutic agents like GM-CSF.

Main Results:

• The novel Ad5/3-RGD D24 virus exhibited potent cytopathic effects in all tested tumor lines at low viral titers.
• This enhanced heterologous oncolysis demonstrated superior cytotoxicity compared to Ad5-RGD D24, Ad5/3 D24, and an HSV oncolytic virus.
• The virus successfully maintained enhanced oncolysis after engineering for GM-CSF delivery.

Conclusions:

• The novel Ad5/3-RGD D24 adenovirus represents a promising platform for oncolytic virotherapy.
• Its enhanced tumor targeting and potent oncolytic activity, combined with the capacity for immunotherapy delivery, suggest significant therapeutic potential for various cancers.